Sona Nanotech Inc.

Recent News

  • Sona Engages Sports Marketing Partner to Secure Concussion Test Development Partner

    Halifax, Nova Scotia--(Newsfile Corp. - August 31, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announced today it has engaged Bonham/Wills & Associates ("Bonham/Wills"), a leading sports consulting firm, to assist in securing test development sponsorship partners for its next rapid-response test R&D project, leveraging the Company's proprietary gold nanorod technology. Bonham/Wills is tasked with identifying partners to participate in the development of a prototype and eventual field validation...

    2020-08-31 8:15 AM ET
  • Sona Nanotech Announces Clinical Evaluation Study Results for its COVID-19 Antigen Test

    Halifax, Nova Scotia--(Newsfile Corp. - August 25, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection COVID-19 antigen test achieved a sensitivity of 84.6% and a specificity of 90.0% in a study across 99 collected clinical patient samples, which included 39 positive samples and 60 negative samples, as determined by RT-PCR testing. The Company is now continuing its submission of data to both...

    2020-08-25 1:34 PM ET
  • Sona Nanotech Clinical In-Field Validation Study Results to Be Released Next Week

    Halifax, Nova Scotia--(Newsfile Corp. - August 20, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announces that it expects to release a report on its clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test next week. This data will be used to support the Company's submissions to Health Canada and the FDA for emergency use authorization ("EUA") approval for its COVID-19 antigen test.The Company is reliant on...

    2020-08-20 9:38 AM ET
  • Sona Nanotech Updates on Timing of Clinical In-Field Validation Studies for its COVID-19 Antigen Test

    Halifax, Nova Scotia--(Newsfile Corp. - August 6, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announces that its previously announced clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test that commenced in July continue and are now expected to return their full results within two weeks. The delays have been due to ethics review board approvals and a need to make study modifications to accommodate regulatory updates,...

    2020-08-06 1:51 PM ET
  • Sona Nanotech Unaware of Any Material Change

    Halifax, Nova Scotia--(Newsfile Corp. - July 23, 2020) - At the request of the Investment Industry Regulatory Organization of Canada ("IIROC") Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.The Company cautions that its COVID-19 rapid antigen test is not yet approved by the FDA or other regulatory bodies and will update...

    2020-07-23 3:03 PM ET
  • RETRANSMISSION: Sona Nanotech Engages Maxim Group for NASDAQ Listing and Investment Banking Services, and Announces Organizational Change

    Halifax, Nova Scotia--(Newsfile Corp. - July 9, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) ("Sona Nanotech" or the "Company"), a developer of rapid, point-of-care diagnostic tests for COVID-19 and other applications, has engaged Maxim Group, LLC ("Maxim") for general financial advisory and investment banking services in relation to its planned application to list the Company's common shares on the NASDAQ Capital Market ("NASDAQ").By up-listing to NASDAQ, the Company aspires to gain new exposure and access to a larger...

    2020-07-09 8:00 AM ET
  • Sona Nanotech Engages Maxim Group for NASDAQ Listing and Investment Banking Services, and Announces Organizational Change

    Halifax, Nova Scotia--(Newsfile Corp. - July 8, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona Nanotech" or the "Company"), a developer of rapid, point-of-care diagnostic tests for COVID-19 and other applications, has engaged Maxim Group, LLC ("Maxim") for general financial advisory and investment banking services in relation to its planned application to list the Company's common shares on the NASDAQ Capital Market ("NASDAQ"). By up-listing to NASDAQ, the Company aspires to gain new exposure and access to...

    2020-07-08 6:41 PM ET
  • Sona Nanotech Announces Validation Results for its COVID-19 Antigen Test

    Halifax, Nova Scotia--(Newsfile Corp. - July 2, 2020) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, is pleased to announce that its rapid detection, COVID-19 antigen test's laboratory validation studies of performance levels have resulted in a test sensitivity of 96%, test specificity of 96% and a Limit of Detection ("LOD") of 2.1 x 102 TCID50. Sales of the tests will now be permitted under a 'research use only' label...

    2020-07-02 2:52 PM ET